APO Research
Talk to an analyst

APO RESEARCH · REPORT

In-vitro Toxicity Testing

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global In-vitro Toxicity Testing Market Outlook and Growth Opportunities 2026

22 December 2025199 pages

Choose your research edition.

Industry ResearchIn-vitro Toxicity Testing Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal In-vitro Toxicity Testing Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal In-vitro Toxicity Testing Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal In-vitro Toxicity Testing Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal In-vitro Toxicity Testing Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global In-vitro Toxicity Testing market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for In-vitro Toxicity Testing is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for In-vitro Toxicity Testing is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for In-vitro Toxicity Testing is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the In-vitro Toxicity Testing market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the In-vitro Toxicity Testing market include Thermo Fisher Scientific Inc., Merck KGaA, Agilent Technologies Inc., General Electric Co., Evotec AG, Eurofins GSC Lux Sarl, Charles River Laboratories International Inc., CELTHER POLSKA Sp z o.o. and Bio-Rad Laboratories Inc., among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global In-vitro Toxicity Testing market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of In-vitro Toxicity Testing and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents In-vitro Toxicity Testing revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global In-vitro Toxicity Testing market.

In-vitro Toxicity Testing Segment by Company

Thermo Fisher Scientific Inc.

Merck KGaA

Agilent Technologies Inc.

General Electric Co.

Evotec AG

Eurofins GSC Lux Sarl

Charles River Laboratories International Inc.

CELTHER POLSKA Sp z o.o.

Bio-Rad Laboratories Inc.

Abbott Laboratories

In-vitro Toxicity Testing Segment by Type

Static Well Plate System

Multi-compartmental Perfused Systems

In-vitro Toxicity Testing Segment by Application

Pharmaceutical and Biotechnology Companies

Academic and Research Institutions

Others

In-vitro Toxicity Testing Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global In-vitro Toxicity Testing status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the In-vitro Toxicity Testing key companies, revenue, market share, and recent developments.

3. To split the In-vitro Toxicity Testing breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions In-vitro Toxicity Testing market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify In-vitro Toxicity Testing significant trends, drivers, influence factors in global and regions.

6. To analyze In-vitro Toxicity Testing competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global In-vitro Toxicity Testing market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of In-vitro Toxicity Testing and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of In-vitro Toxicity Testing.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global In-vitro Toxicity Testing industry.

Chapter 3: Detailed analysis of In-vitro Toxicity Testing company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of In-vitro Toxicity Testing in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of In-vitro Toxicity Testing in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. In-vitro Toxicity Testing Industry Trends Table 2. In-vitro Toxicity Testing Industry Drivers Table 3. In-vitro Toxicity Testing Industry Opportunities and Challenges Table 4. In-vitro Toxicity Testing Industry Restraints Table 5. Global In-vitro Toxicity Testing Revenue by Company (US$ Million) & (2021-2026) Table 6. Global In-vitro Toxicity Testing Revenue Share by Company (2021-2026) Table 7. Global In-vitro Toxicity Testing Company Ranking, (2024-2026) & (US$ Million) Table 8. Global In-vitro Toxicity Testing Key Company Manufacturing Base & Headquarters Table 9. Global In-vitro Toxicity Testing Company, Product Type & Application Table 10. Global In-vitro Toxicity Testing Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global In-vitro Toxicity Testing by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Static Well Plate System Table 15. Significant Companies of Multi-compartmental Perfused Systems Table 16. Global In-vitro Toxicity Testing Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global In-vitro Toxicity Testing Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global In-vitro Toxicity Testing Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global In-vitro Toxicity Testing Sales Value Share by Type (2021-2026) Table 20. Global In-vitro Toxicity Testing Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Pharmaceutical and Biotechnology Companies Table 22. Significant Companies of Academic and Research Institutions Table 23. Significant Companies of Others Table 24. Global In-vitro Toxicity Testing Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global In-vitro Toxicity Testing Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global In-vitro Toxicity Testing Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global In-vitro Toxicity Testing Sales Value Share by Application (2021-2026) Table 28. Global In-vitro Toxicity Testing Sales Value Share by Application (2027-2032) Table 29. Global In-vitro Toxicity Testing Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global In-vitro Toxicity Testing Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global In-vitro Toxicity Testing Sales Value Share by Region (2021-2026) Table 32. Global In-vitro Toxicity Testing Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global In-vitro Toxicity Testing Sales Value Share by Region (2027-2032) Table 34. Global In-vitro Toxicity Testing Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global In-vitro Toxicity Testing Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global In-vitro Toxicity Testing Sales Value Market Share by Country (2021-2026) Table 37. Global In-vitro Toxicity Testing Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global In-vitro Toxicity Testing Sales Value Market Share by Country (2027-2032) Table 39. Thermo Fisher Scientific Inc. Company Information Table 40. Thermo Fisher Scientific Inc. Business Overview Table 41. Thermo Fisher Scientific Inc. In-vitro Toxicity Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Thermo Fisher Scientific Inc. In-vitro Toxicity Testing Product Portfolio Table 43. Thermo Fisher Scientific Inc. Recent Development Table 44. Merck KGaA Company Information Table 45. Merck KGaA Business Overview Table 46. Merck KGaA In-vitro Toxicity Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Merck KGaA In-vitro Toxicity Testing Product Portfolio Table 48. Merck KGaA Recent Development Table 49. Agilent Technologies Inc. Company Information Table 50. Agilent Technologies Inc. Business Overview Table 51. Agilent Technologies Inc. In-vitro Toxicity Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Agilent Technologies Inc. In-vitro Toxicity Testing Product Portfolio Table 53. Agilent Technologies Inc. Recent Development Table 54. General Electric Co. Company Information Table 55. General Electric Co. Business Overview Table 56. General Electric Co. In-vitro Toxicity Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. General Electric Co. In-vitro Toxicity Testing Product Portfolio Table 58. General Electric Co. Recent Development Table 59. Evotec AG Company Information Table 60. Evotec AG Business Overview Table 61. Evotec AG In-vitro Toxicity Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Evotec AG In-vitro Toxicity Testing Product Portfolio Table 63. Evotec AG Recent Development Table 64. Eurofins GSC Lux Sarl Company Information Table 65. Eurofins GSC Lux Sarl Business Overview Table 66. Eurofins GSC Lux Sarl In-vitro Toxicity Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Eurofins GSC Lux Sarl In-vitro Toxicity Testing Product Portfolio Table 68. Eurofins GSC Lux Sarl Recent Development Table 69. Charles River Laboratories International Inc. Company Information Table 70. Charles River Laboratories International Inc. Business Overview Table 71. Charles River Laboratories International Inc. In-vitro Toxicity Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Charles River Laboratories International Inc. In-vitro Toxicity Testing Product Portfolio Table 73. Charles River Laboratories International Inc. Recent Development Table 74. CELTHER POLSKA Sp z o.o. Company Information Table 75. CELTHER POLSKA Sp z o.o. Business Overview Table 76. CELTHER POLSKA Sp z o.o. In-vitro Toxicity Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. CELTHER POLSKA Sp z o.o. In-vitro Toxicity Testing Product Portfolio Table 78. CELTHER POLSKA Sp z o.o. Recent Development Table 79. Bio-Rad Laboratories Inc. Company Information Table 80. Bio-Rad Laboratories Inc. Business Overview Table 81. Bio-Rad Laboratories Inc. In-vitro Toxicity Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Bio-Rad Laboratories Inc. In-vitro Toxicity Testing Product Portfolio Table 83. Bio-Rad Laboratories Inc. Recent Development Table 84. Abbott Laboratories Company Information Table 85. Abbott Laboratories Business Overview Table 86. Abbott Laboratories In-vitro Toxicity Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Abbott Laboratories In-vitro Toxicity Testing Product Portfolio Table 88. Abbott Laboratories Recent Development Table 89. Research Programs/Design for This Report Table 90. Authors List of This Report Table 91. Secondary Sources Table 92. Primary Sources List of Figures Figure 1. In-vitro Toxicity Testing Product Image Figure 2. Global In-vitro Toxicity Testing Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global In-vitro Toxicity Testing Market Size (2021-2032) & (US$ Million) Figure 4. Global In-vitro Toxicity Testing Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Static Well Plate System Image Figure 8. Multi-compartmental Perfused Systems Image Figure 9. Global In-vitro Toxicity Testing Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global In-vitro Toxicity Testing Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global In-vitro Toxicity Testing Sales Value Share by Type (2021-2032) Figure 12. Pharmaceutical and Biotechnology Companies Image Figure 13. Academic and Research Institutions Image Figure 14. Others Image Figure 15. Global In-vitro Toxicity Testing Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global In-vitro Toxicity Testing Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global In-vitro Toxicity Testing Sales Value Share by Application (2021-2032) Figure 18. Global In-vitro Toxicity Testing Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global In-vitro Toxicity Testing Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America In-vitro Toxicity Testing Sales Value (2021-2032) & (US$ Million) Figure 21. North America In-vitro Toxicity Testing Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe In-vitro Toxicity Testing Sales Value (2021-2032) & (US$ Million) Figure 23. Europe In-vitro Toxicity Testing Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific In-vitro Toxicity Testing Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific In-vitro Toxicity Testing Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America In-vitro Toxicity Testing Sales Value (2021-2032) & (US$ Million) Figure 27. South America In-vitro Toxicity Testing Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa In-vitro Toxicity Testing Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa In-vitro Toxicity Testing Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA In-vitro Toxicity Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA In-vitro Toxicity Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA In-vitro Toxicity Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada In-vitro Toxicity Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada In-vitro Toxicity Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada In-vitro Toxicity Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico In-vitro Toxicity Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico In-vitro Toxicity Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico In-vitro Toxicity Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany In-vitro Toxicity Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany In-vitro Toxicity Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany In-vitro Toxicity Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France In-vitro Toxicity Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France In-vitro Toxicity Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France In-vitro Toxicity Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. In-vitro Toxicity Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. In-vitro Toxicity Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. In-vitro Toxicity Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy In-vitro Toxicity Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy In-vitro Toxicity Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy In-vitro Toxicity Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain In-vitro Toxicity Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain In-vitro Toxicity Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain In-vitro Toxicity Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia In-vitro Toxicity Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia In-vitro Toxicity Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia In-vitro Toxicity Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands In-vitro Toxicity Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands In-vitro Toxicity Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands In-vitro Toxicity Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries In-vitro Toxicity Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries In-vitro Toxicity Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries In-vitro Toxicity Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China In-vitro Toxicity Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China In-vitro Toxicity Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China In-vitro Toxicity Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan In-vitro Toxicity Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan In-vitro Toxicity Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan In-vitro Toxicity Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea In-vitro Toxicity Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea In-vitro Toxicity Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea In-vitro Toxicity Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India In-vitro Toxicity Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India In-vitro Toxicity Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India In-vitro Toxicity Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia In-vitro Toxicity Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia In-vitro Toxicity Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia In-vitro Toxicity Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia In-vitro Toxicity Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia In-vitro Toxicity Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia In-vitro Toxicity Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil In-vitro Toxicity Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil In-vitro Toxicity Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil In-vitro Toxicity Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina In-vitro Toxicity Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina In-vitro Toxicity Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina In-vitro Toxicity Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile In-vitro Toxicity Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile In-vitro Toxicity Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile In-vitro Toxicity Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia In-vitro Toxicity Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia In-vitro Toxicity Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia In-vitro Toxicity Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru In-vitro Toxicity Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru In-vitro Toxicity Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru In-vitro Toxicity Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia In-vitro Toxicity Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia In-vitro Toxicity Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia In-vitro Toxicity Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel In-vitro Toxicity Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel In-vitro Toxicity Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel In-vitro Toxicity Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE In-vitro Toxicity Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE In-vitro Toxicity Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE In-vitro Toxicity Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey In-vitro Toxicity Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey In-vitro Toxicity Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey In-vitro Toxicity Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran In-vitro Toxicity Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran In-vitro Toxicity Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran In-vitro Toxicity Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt In-vitro Toxicity Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt In-vitro Toxicity Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt In-vitro Toxicity Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • Static Well Plate System
  • Multi-compartmental Perfused Systems
Applications
  • Pharmaceutical and Biotechnology Companies
  • Academic and Research Institutions
  • Others
Companies covered
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Agilent Technologies Inc.
  • General Electric Co.
  • Evotec AG
  • Eurofins GSC Lux Sarl
  • Charles River Laboratories International Inc.
  • CELTHER POLSKA Sp z o.o.
  • Bio-Rad Laboratories Inc.
  • Abbott Laboratories

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global In-vitro Toxicity Testing Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global In-vitro Toxicity Testing Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 In-vitro Toxicity Testing Market Dynamics
  1. 2.1 In-vitro Toxicity Testing Industry Trends
  2. 2.2 In-vitro Toxicity Testing Industry Drivers
  3. 2.3 In-vitro Toxicity Testing Industry Opportunities and Challenges
  4. 2.4 In-vitro Toxicity Testing Industry Restraints
3 In-vitro Toxicity Testing Market by Company
  1. 3.1 Global In-vitro Toxicity Testing Company Revenue Ranking in 2025
  2. 3.2 Global In-vitro Toxicity Testing Revenue by Company (2021-2026)
  3. 3.3 Global In-vitro Toxicity Testing Company Ranking (2024-2026)
  4. 3.4 Global In-vitro Toxicity Testing Company Manufacturing Base and Headquarters
  5. 3.5 Global In-vitro Toxicity Testing Company Product Type and Application
  6. 3.6 Global In-vitro Toxicity Testing Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global In-vitro Toxicity Testing Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 In-vitro Toxicity Testing Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 In-vitro Toxicity Testing Market by Type
  1. 4.1 In-vitro Toxicity Testing Type Introduction
  2. 4.1.1 Static Well Plate System
  3. 4.1.2 Multi-compartmental Perfused Systems
  4. 4.2 Global In-vitro Toxicity Testing Sales Value by Type
  5. 4.2.1 Global In-vitro Toxicity Testing Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global In-vitro Toxicity Testing Sales Value by Type (2021-2032)
  7. 4.2.3 Global In-vitro Toxicity Testing Sales Value Share by Type (2021-2032)
5 In-vitro Toxicity Testing Market by Application
  1. 5.1 In-vitro Toxicity Testing Application Introduction
  2. 5.1.1 Pharmaceutical and Biotechnology Companies
  3. 5.1.2 Academic and Research Institutions
  4. 5.1.3 Others
  5. 5.2 Global In-vitro Toxicity Testing Sales Value by Application
  6. 5.2.1 Global In-vitro Toxicity Testing Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global In-vitro Toxicity Testing Sales Value by Application (2021-2032)
  8. 5.2.3 Global In-vitro Toxicity Testing Sales Value Share by Application (2021-2032)
6 In-vitro Toxicity Testing Regional Value Analysis
  1. 6.1 Global In-vitro Toxicity Testing Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global In-vitro Toxicity Testing Sales Value by Region (2021-2032)
  3. 6.2.1 Global In-vitro Toxicity Testing Sales Value by Region: 2021-2026
  4. 6.2.2 Global In-vitro Toxicity Testing Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America In-vitro Toxicity Testing Sales Value (2021-2032)
  7. 6.3.2 North America In-vitro Toxicity Testing Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe In-vitro Toxicity Testing Sales Value (2021-2032)
  10. 6.4.2 Europe In-vitro Toxicity Testing Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific In-vitro Toxicity Testing Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific In-vitro Toxicity Testing Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America In-vitro Toxicity Testing Sales Value (2021-2032)
  16. 6.6.2 South America In-vitro Toxicity Testing Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa In-vitro Toxicity Testing Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa In-vitro Toxicity Testing Sales Value Share by Country, 2025 VS 2032
7 In-vitro Toxicity Testing Country-level Value Analysis
  1. 7.1 Global In-vitro Toxicity Testing Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global In-vitro Toxicity Testing Sales Value by Country (2021-2032)
  3. 7.2.1 Global In-vitro Toxicity Testing Sales Value by Country (2021-2026)
  4. 7.2.2 Global In-vitro Toxicity Testing Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA In-vitro Toxicity Testing Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA In-vitro Toxicity Testing Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA In-vitro Toxicity Testing Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada In-vitro Toxicity Testing Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada In-vitro Toxicity Testing Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada In-vitro Toxicity Testing Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico In-vitro Toxicity Testing Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico In-vitro Toxicity Testing Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico In-vitro Toxicity Testing Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany In-vitro Toxicity Testing Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany In-vitro Toxicity Testing Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany In-vitro Toxicity Testing Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France In-vitro Toxicity Testing Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France In-vitro Toxicity Testing Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France In-vitro Toxicity Testing Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. In-vitro Toxicity Testing Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. In-vitro Toxicity Testing Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. In-vitro Toxicity Testing Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy In-vitro Toxicity Testing Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy In-vitro Toxicity Testing Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy In-vitro Toxicity Testing Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain In-vitro Toxicity Testing Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain In-vitro Toxicity Testing Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain In-vitro Toxicity Testing Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia In-vitro Toxicity Testing Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia In-vitro Toxicity Testing Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia In-vitro Toxicity Testing Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands In-vitro Toxicity Testing Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands In-vitro Toxicity Testing Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands In-vitro Toxicity Testing Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries In-vitro Toxicity Testing Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries In-vitro Toxicity Testing Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries In-vitro Toxicity Testing Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China In-vitro Toxicity Testing Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China In-vitro Toxicity Testing Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China In-vitro Toxicity Testing Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan In-vitro Toxicity Testing Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan In-vitro Toxicity Testing Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan In-vitro Toxicity Testing Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea In-vitro Toxicity Testing Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea In-vitro Toxicity Testing Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea In-vitro Toxicity Testing Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India In-vitro Toxicity Testing Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India In-vitro Toxicity Testing Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India In-vitro Toxicity Testing Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia In-vitro Toxicity Testing Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia In-vitro Toxicity Testing Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia In-vitro Toxicity Testing Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia In-vitro Toxicity Testing Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia In-vitro Toxicity Testing Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia In-vitro Toxicity Testing Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil In-vitro Toxicity Testing Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil In-vitro Toxicity Testing Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil In-vitro Toxicity Testing Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina In-vitro Toxicity Testing Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina In-vitro Toxicity Testing Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina In-vitro Toxicity Testing Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile In-vitro Toxicity Testing Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile In-vitro Toxicity Testing Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile In-vitro Toxicity Testing Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia In-vitro Toxicity Testing Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia In-vitro Toxicity Testing Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia In-vitro Toxicity Testing Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru In-vitro Toxicity Testing Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru In-vitro Toxicity Testing Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru In-vitro Toxicity Testing Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia In-vitro Toxicity Testing Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia In-vitro Toxicity Testing Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia In-vitro Toxicity Testing Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel In-vitro Toxicity Testing Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel In-vitro Toxicity Testing Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel In-vitro Toxicity Testing Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE In-vitro Toxicity Testing Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE In-vitro Toxicity Testing Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE In-vitro Toxicity Testing Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey In-vitro Toxicity Testing Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey In-vitro Toxicity Testing Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey In-vitro Toxicity Testing Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran In-vitro Toxicity Testing Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran In-vitro Toxicity Testing Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran In-vitro Toxicity Testing Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt In-vitro Toxicity Testing Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt In-vitro Toxicity Testing Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt In-vitro Toxicity Testing Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Thermo Fisher Scientific Inc.
  2. 8.1.1 Thermo Fisher Scientific Inc. Company Information
  3. 8.1.2 Thermo Fisher Scientific Inc. Business Overview
  4. 8.1.3 Thermo Fisher Scientific Inc. In-vitro Toxicity Testing Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Thermo Fisher Scientific Inc. In-vitro Toxicity Testing Product Portfolio
  6. 8.1.5 Thermo Fisher Scientific Inc. Recent Developments
  7. 8.2 Merck KGaA
  8. 8.2.1 Merck KGaA Company Information
  9. 8.2.2 Merck KGaA Business Overview
  10. 8.2.3 Merck KGaA In-vitro Toxicity Testing Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Merck KGaA In-vitro Toxicity Testing Product Portfolio
  12. 8.2.5 Merck KGaA Recent Developments
  13. 8.3 Agilent Technologies Inc.
  14. 8.3.1 Agilent Technologies Inc. Company Information
  15. 8.3.2 Agilent Technologies Inc. Business Overview
  16. 8.3.3 Agilent Technologies Inc. In-vitro Toxicity Testing Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Agilent Technologies Inc. In-vitro Toxicity Testing Product Portfolio
  18. 8.3.5 Agilent Technologies Inc. Recent Developments
  19. 8.4 General Electric Co.
  20. 8.4.1 General Electric Co. Company Information
  21. 8.4.2 General Electric Co. Business Overview
  22. 8.4.3 General Electric Co. In-vitro Toxicity Testing Revenue and Gross Margin (2021-2026)
  23. 8.4.4 General Electric Co. In-vitro Toxicity Testing Product Portfolio
  24. 8.4.5 General Electric Co. Recent Developments
  25. 8.5 Evotec AG
  26. 8.5.1 Evotec AG Company Information
  27. 8.5.2 Evotec AG Business Overview
  28. 8.5.3 Evotec AG In-vitro Toxicity Testing Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Evotec AG In-vitro Toxicity Testing Product Portfolio
  30. 8.5.5 Evotec AG Recent Developments
  31. 8.6 Eurofins GSC Lux Sarl
  32. 8.6.1 Eurofins GSC Lux Sarl Company Information
  33. 8.6.2 Eurofins GSC Lux Sarl Business Overview
  34. 8.6.3 Eurofins GSC Lux Sarl In-vitro Toxicity Testing Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Eurofins GSC Lux Sarl In-vitro Toxicity Testing Product Portfolio
  36. 8.6.5 Eurofins GSC Lux Sarl Recent Developments
  37. 8.7 Charles River Laboratories International Inc.
  38. 8.7.1 Charles River Laboratories International Inc. Company Information
  39. 8.7.2 Charles River Laboratories International Inc. Business Overview
  40. 8.7.3 Charles River Laboratories International Inc. In-vitro Toxicity Testing Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Charles River Laboratories International Inc. In-vitro Toxicity Testing Product Portfolio
  42. 8.7.5 Charles River Laboratories International Inc. Recent Developments
  43. 8.8 CELTHER POLSKA Sp z o.o.
  44. 8.8.1 CELTHER POLSKA Sp z o.o. Company Information
  45. 8.8.2 CELTHER POLSKA Sp z o.o. Business Overview
  46. 8.8.3 CELTHER POLSKA Sp z o.o. In-vitro Toxicity Testing Revenue and Gross Margin (2021-2026)
  47. 8.8.4 CELTHER POLSKA Sp z o.o. In-vitro Toxicity Testing Product Portfolio
  48. 8.8.5 CELTHER POLSKA Sp z o.o. Recent Developments
  49. 8.9 Bio-Rad Laboratories Inc.
  50. 8.9.1 Bio-Rad Laboratories Inc. Company Information
  51. 8.9.2 Bio-Rad Laboratories Inc. Business Overview
  52. 8.9.3 Bio-Rad Laboratories Inc. In-vitro Toxicity Testing Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Bio-Rad Laboratories Inc. In-vitro Toxicity Testing Product Portfolio
  54. 8.9.5 Bio-Rad Laboratories Inc. Recent Developments
  55. 8.10 Abbott Laboratories
  56. 8.10.1 Abbott Laboratories Company Information
  57. 8.10.2 Abbott Laboratories Business Overview
  58. 8.10.3 Abbott Laboratories In-vitro Toxicity Testing Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Abbott Laboratories In-vitro Toxicity Testing Product Portfolio
  60. 8.10.5 Abbott Laboratories Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst